4.7 Article

Exploring Next Generation Probiotics for Metabolic and Microbiota Dysbiosis Linked to Xenobiotic Exposure: Holistic Approach

Journal

Publisher

MDPI
DOI: 10.3390/ijms232112917

Keywords

Microbiota Disrupting Chemicals (MDCs); microbiota; metabolites; Next Generation Probiotics (NGPs); xenobiotics

Funding

  1. FEDER Project Infrastructure [IE_2019-198]
  2. Instituto de Salud Carlos III [PI20/01278]
  3. FIBAO
  4. EU-FORA Programme (2020/2021)

Ask authors/readers for more resources

Variation of gut microbiota in metabolic diseases is related to dysbiosis induced by exposure to Microbiota Disrupting Chemicals (MDCs). Recent studies have focused on identifying key targets involved in the severity of the host disease triggered by xenobiotics. Understanding the triad of xenobiotic-microbiota-metabolic diseases can help prevent or treat health imbalances by identifying beneficial microbe taxa and developing mitigation strategies.
Variation of gut microbiota in metabolic diseases seems to be related to dysbiosis induced by exposure to multiple substances called Microbiota Disrupting Chemicals (MDCs), which are present as environmental and dietary contaminants. Some recent studies have focused on elucidating the alterations of gut microbiota taxa and their metabolites as a consequence of xenobiotic exposures to find possible key targets involved in the severity of the host disease triggered. Compilation of data supporting the triad of xenobiotic-microbiota-metabolic diseases would subsequently allow such health misbalances to be prevented or treated by identifying beneficial microbe taxa that could be Next Generation Probiotics (NGPs) with metabolic enzymes for MDC neutralisation and mitigation strategies. In this review, we aim to compile the available information and reports focused on variations of the main gut microbiota taxa in metabolic diseases associated with xenobiotic exposure and related microbial metabolite profiles impacting the host health status. We performed an extensive literature search using SCOPUS, Web of Science, and PubMed databases. The data retrieval and thorough analyses highlight the need for more combined metagenomic and metabolomic studies revealing signatures for xenobiotics and triggered metabolic diseases. Moreover, metabolome and microbiome compositional taxa analyses allow further exploration of how to target beneficial NGP candidates according to their alleged variability abundance and potential therapeutic significance. Furthermore, this holistic approach has identified limitations and the need of future directions to expand and integrate key knowledge to design appropriate clinical and interventional studies with NGPs. Apart from human health, the beneficial microbes and metabolites identified could also be proposed for various applications under One Health, such as probiotics for animals, plants and environmental bioremediation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available